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Introduction
Pituitary apoplexy is an uncommon clinical syndrome
caused by sudden hemorrhage or infarction of pituitary
tumors. It is characterized by acute onset of headache,
accompanied by vomiting and frequently followed by
visual deterioration and ophthalmoplegia. Apoplexy 
is usually spontaneous, but it may be associated with
numerous pathologic states and medications, such 
as head trauma,1–3 arterial hypertension,2 increased
intracranial pressure,1–3 radiotherapy,1,3 diabetic keto-
acidosis,2–4 anticoagulation,1–3 estrogens,1,2 and bro-
mocriptine.1,2,5 The possible relationship between the
predisposing conditions and the occurrence of pituitary
apoplexy may be pituitary necrosis, hemorrhage, or vas-
culopathy, although the exact mechanism is unclear.1,3–5
Pituitary apoplexy associated with dynamic testing of
the pituitary gland is extremely rare.6–8 Patients with
this medical emergency need prompt diagnosis for
appropriate management. Computed tomography (CT)
and magnetic resonance imaging (MRI) play important
roles in confirming the diagnosis by revealing a pituitary
tumor with hemorrhage and/or necrotic components.
In this report, we present a patient who developed pitu-
itary apoplexy 2 hours after injection of thyrotropin-
releasing hormone (TRH). CT and MRI studies failed
to demonstrate pituitary hemorrhage or infarction.
Case Report
A 41-year-old female presented to our clinic for further
evaluation of her goiter, which was discovered recently.
However, acromegaloid picture, accompanied by 5-year
history of dysmenorrhea followed by 2-year history 
of amenorrhea made the presence of pituitary tumor
highly probable. Thus, she was admitted to the hospital
for investigation of pituitary tumor with acromegaly.
At the time of admission, the patient’s blood pres-
sure was 145/93 mmHg and heart rate was 91 beats
per minute. Smooth respiratory pattern, goiter (grade
II), galactorrhea, increased size of hands and feet, as
well as coarse facial contours were noted. Visual acuity
was 6/12 in both eyes, and visual field examination
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signified a bitemporal upper field defect. Extraocular
muscle movements were normal. Fasting plasma glu-
cose level was 154 mg/dL, and diabetes pattern was
also noted by oral glucose tolerance test (OGTT).
Basal growth hormone (GH) level (353 ng/mL) was
high, and there was no suppression of GH during 
the OGTT. The basal endocrine function test results
are shown in Table 1. Paradoxical GH responses to L-
dopa, gonadotropin-releasing hormone (GnRH) and
TRH are demonstrated in Figure 1. Plain skull X-ray
Table 1. Pituitary hormones and relative biochemical data
Pre-op 3 d post-op 17 d post-op 2 mo post-op
GH (N < 5 ng/mL) 353 4.11 3.96
IGF-1 (N 100–276 ng/mL) 1,076 869 686
PRL (N 3–26 ng/mL) 4.03 0.13 0.11
TSH (N 0.4–4 µIU/mL) 1.19 0.34 1.25 0.42
Free T4 (N 0.8–1.9 ng/dL) 1.39 0.85 1.26 1.37
T3 (N 82–179 ng/dL) 147 56.79 152 119
ACTH (N 9–52 pg/mL) AM 29, PM 14.5 AM 27
TgAb (N < 60 U/mL) 6.2
TPOAb (N < 60 U/mL) 24.7
Cortisol (AM) (N 5–25 µg/dL) 18.42 15.8 10.2 9.264
Cortisol (PM) (N < 5 µg/dL) 7.73
LH (IU/L) 0.24 0.18 0.78
FSH (IU/L) 1.33 0.07 0.72
E2 (pg/mL) 16.58 16.09 20.58 24.10
ADH (N 0.4–2.4 pg/mL) 0.97
Plasma osmolality (mOsm/kg) 290
Urine osmolality (mOsm/kg) 193
iPHT (N < 50 pg/mL) 42.05
Ca (N 8.4–10.6 mg/dL) 9.6
op = operation; GH = growth hormone; N = normal; IGF-1 = insulin-like growth factor-1; PRL = prolactin; TSH = thyroid-stimulating hormone; T4 = thyroxine; T3 =
triiodothyronine; ACTH = adrenocorticotropic hormone; TgAb = thyroglobulin antibody; TPOAb = thyroid peroxidase antibody; LH = luteinizing hormone; FSH =
follicle-stimulating hormone; E2 = estradiol; ADH = antidiuretic hormone; iPTH = intact parathyroid hormone.
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Figure 1. Serum growth hormone (GH) levels during L-dopa, gonadotropin-releasing hormone (GnRH) and thyrotropin-releasing hormone
(TRH) tests.
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films illustrated erosion and destruction of pituitary
fossa. MRI performed the day before TRH stimula-
tion test revealed a lobulated pituitary macroadenoma
(38 × 31× 25 mm) with suprasellar extension, compres-
sion of optic chiasm, and invasion of left cavernous
sinus (Figure 2A). About 2 hours after a bolus injection
of 200 µg TRH, the patient had a sudden and intense
headache, cold sweating, visual disturbance, ptosis,
and diplopia. Blood pressure was 157/82 mmHg,
heart rate was 50 beats per minute, and glucose level
was 94 mg/dL. Emergency CT showed neither intra-
tumoral hemorrhage nor infarction. Since pituitary
apoplexy was highly suspected clinically, MRI was
performed 12 hours after the episode, which dis-
closed no hemorrhage within the tumor (Figure 2B),
but slight increase in tumor size (from 15.26 cm3 to
16.15 cm3) compared with the previous MRI image.
The patient was administered hydrocortisone (300mg/
day) intravenously, and her headache and diplopia
partially improved.
Two days later, the tumor was removed by trans-
sphenoidal approach. Microscopic study indicated a
picture of pituitary adenoma with fresh hemorrhage
and ischemic necrosis. Immunohistochemically, the
tumor was positive for GH, follicle-stimulating hor-
mone, and alpha-subunit. On the second postoperative
day, the symptoms mentioned above had all subsided
except for diplopia. The follow-up hormone levels are
shown in Table 1. One month after the operation, the
patient was well without steroid hormone replacement.
Three months after operation, her extraocular muscle
movements were nearly normal, and the diplopia had
disappeared.
Discussion
The very high basal GH level, up to 353 ng/mL in our
case, confirmed the diagnosis of active acromegaly.
However, acromegalic patients have both increased
plasma levels of GH and a deranged pattern of GH
secretion. About 50–80% of acromegalic patients will
have GH > 50% of the basal level after TRH stimula-
tion, and less frequently in response to GnRH.9–11 In
addition, half of acromegalic patients may have a par-
adoxical response to L-dopa.9,10 Elevation and suppres-
sion of GH after TRH and L-dopa disclosed abnormal
GH secretion dynamics in our case.
Pituitary apoplexy is a rare clinical syndrome caused
by sudden hemorrhage or infarction of the pituitary
gland. Headache is the initial and leading symptom of
pituitary apoplexy.12 Ocular palsy is also frequent, due
to functional impairment of cranial nerves III, IV and
VI.2,13 Though apoplectic symptoms frequently occur
within minutes or hours after pituitary apoplexy, it
has been reported that they may transpire several days
later.6 The possible causes of pituitary apoplexy have
been reported, but the precise mechanism of apoplexy
is not fully understood.1,3,6–8 Pituitary stimulation tests
are extremely rare causes of pituitary apoplexy.6–8 In a
review of 22 reports of pituitary apoplexy after a pitu-
itary function test, TRH was responsible for 15 cases
A B
Figure 2. Magnetic resonance imaging coronal T1-weighted images show pituitary macroadenoma (arrow) without evidence of pituitary
apoplexy: (A) before thyrotropin-releasing hormone (TRH) test; (B) after TRH test.
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of apoplectic events.8 Direct vasospasm effect may 
be the cause of TRH-induced pituitary apoplexy. In
our case, the pituitary apoplexy was noticed shortly
after TRH injection, which was quite similar to other
reports.6–8 This supported a causal relationship rather
than spontaneous occurrence.
CT is useful in the acute setting (24–48 hours),
and the most reliable CT sign of pituitary apoplexy is
the presence of a homogeneously dense lesion show-
ing little or no enhancement of a high density fluid
level inside the tumor.1,2 However, CT often fails to
show a small hemorrhage or infarction. MRI is supe-
rior to CT in these aspects.14 Randeva et al reported
that MRI correctly demonstrated 88% of pituitary
tumors with hemorrhage, but it was only 21% for CT.13
One limitation of MRI scans is their inability to detect
fresh bleeding, so they are performed at least 12 hours
after the onset of symptoms to eliminate false-negative
scan taken during the hyperacute stage.15 Also, MRI
has been shown to be useful for identifying blood com-
ponents in the subacute setting (4 days to 1 month).2
Although TRH test is a generally safe test for eval-
uation of pituitary function, pituitary apoplexy may
occur after the procedure, especially in patients with a
large adenoma. CT and MRI are good techniques for
brain imaging, but occasionally, these examinations may
miss the diagnosis of pituitary apoplexy, especially when
performed immediately after the acute episode.
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